MedPath

Amgen, Inc.

Amgen, Inc. logo
🇺🇸United States
Ownership
Public
Established
1980-01-01
Employees
26.7K
Market Cap
$175.6B
Website
http://www.amgen.com
Clinical Trials
Related News

Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis

Phase 1
Completed
Conditions
Cystic Fibrosis
Interventions
Drug: placebo
Drug: MP-376 (Levofloxacin solution for Inhalation)
First Posted Date
2007-07-18
Last Posted Date
2024-12-04
Lead Sponsor
Amgen
Target Recruit Count
40
Registration Number
NCT00503490

Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer

Phase 2
Completed
Conditions
Head and Neck Cancer
Squamous Cell Carcinoma
Interventions
Radiation: Standard Fractionation Radiotherapy
First Posted Date
2007-07-13
Last Posted Date
2018-10-17
Lead Sponsor
Amgen
Target Recruit Count
153
Registration Number
NCT00500760

Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)

Not Applicable
Completed
Conditions
Hematology
MDS
Myelodysplastic Syndromes
Thrombocytopenia
Interventions
First Posted Date
2007-05-11
Last Posted Date
2017-12-29
Lead Sponsor
Amgen
Target Recruit Count
72
Registration Number
NCT00472290

AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib

Phase 2
Completed
Conditions
Advanced Renal Cell Carcinoma
Interventions
Drug: AMG 386 placebo IV
First Posted Date
2007-04-27
Last Posted Date
2016-03-23
Lead Sponsor
Amgen
Target Recruit Count
152
Registration Number
NCT00467025

Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer

Phase 3
Completed
Conditions
Recurrent and/or Metastatic Head and Neck Cancer
Interventions
Drug: ARM 2
Drug: ARM 1
First Posted Date
2007-04-13
Last Posted Date
2014-03-07
Lead Sponsor
Amgen
Target Recruit Count
658
Registration Number
NCT00460265

MONET1-MOtesanib NSCLC Efficacy and Tolerability Study

Phase 3
Terminated
Conditions
Non-Small Cell Lung Cancer
Interventions
Drug: placebo
First Posted Date
2007-04-13
Last Posted Date
2015-09-07
Lead Sponsor
Amgen
Target Recruit Count
1450
Registration Number
NCT00460317

Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Completed
Conditions
Thrombocytopenia
Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Idiopathic Thrombocytopenic Purpura
Thrombocytopenic Purpura
Interventions
Other: Retrospective Chart Review
Other: Patient-reported Outcome Questionnaires
Other: Physician Survey
First Posted Date
2007-04-02
Last Posted Date
2013-11-26
Lead Sponsor
Amgen
Target Recruit Count
326
Registration Number
NCT00454857

PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response

Phase 2
Completed
Conditions
Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck
Interventions
First Posted Date
2007-04-02
Last Posted Date
2018-10-17
Lead Sponsor
Amgen
Target Recruit Count
113
Registration Number
NCT00454779
Locations
🇪🇸

Research Site, Madrid, Spain

Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment

Phase 3
Completed
Conditions
Ulcer
Interventions
First Posted Date
2007-03-22
Last Posted Date
2024-12-16
Lead Sponsor
Amgen
Target Recruit Count
906
Registration Number
NCT00450216

Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers

Phase 3
Completed
Conditions
Peptic Ulcer
Interventions
First Posted Date
2007-03-22
Last Posted Date
2024-12-16
Lead Sponsor
Amgen
Target Recruit Count
627
Registration Number
NCT00450658
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy